Patents by Inventor Juan Pablo Frais

Juan Pablo Frais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220211306
    Abstract: Glucose exposure can be indicative of a number of potential underlying health conditions. The present disclosure is directed to measuring glucose exposure, determined, for example, on an hourly basis. This glucose exposure, in at least one embodiment, represents a current glucose level over the span of given period (e.g., a portion of 24 hours). If a patient's glucose exposure exceeds a glucose threshold or limit (for a 24 hour period in some embodiments), then a variety of treatments may be administered to the patient to help lower overall glucose exposure (e.g., during the 24 hour period).
    Type: Application
    Filed: February 24, 2022
    Publication date: July 7, 2022
    Inventors: Harold Philpott Southerland, III, Todd Furneaux, Juan Pablo Frais, Roger Steven Mazze
  • Patent number: 11284818
    Abstract: Glucose exposure can be indicative of a number of potential underlying health conditions. The present disclosure is directed to measuring glucose exposure, determined, for example, on an hourly basis. This glucose exposure, in at least one embodiment, represents a current glucose level over the span of given period (e.g., a portion of 24 hours). If a patient's glucose exposure exceeds a glucose threshold or limit (for a 24 hour period in some embodiments), then a variety of treatments may be administered to the patient to help lower overall glucose exposure (e.g., during the 24 hour period).
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: March 29, 2022
    Assignee: TT1 Products, Inc.
    Inventors: Harold Philpott Southerland, III, Todd Furneaux, Juan Pablo Frais, Roger Steven Mazze
  • Publication number: 20220061708
    Abstract: Glucose exposure can be indicative of a number of potential underlying health conditions. The present disclosure is directed to measuring glucose exposure, determined, for example, on an hourly basis. This glucose exposure, in at least one embodiment, represents a current glucose level over the span of given period (e.g., a portion of 24 hours). If a patient's glucose exposure exceeds a glucose threshold or limit (for a 24 hour period in some embodiments), then a variety of treatments may be administered to the patient to help lower overall glucose exposure (e.g., during the 24 hour period).
    Type: Application
    Filed: August 31, 2020
    Publication date: March 3, 2022
    Inventors: Harold Philpott Southerland, III, Todd Furneaux, Juan Pablo Frais, Roger Steven Mazze